Outlook Therapeutics, Inc.
OTLK
$0.70
-$0.02-2.40%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 30.53% | 29.70% | 5.91% | -204.79% | -187.67% |
| Gross Profit | -28.68% | -28.56% | 4.56% | 212.07% | 187.67% |
| SG&A Expenses | -1.35% | 1.41% | 33.39% | 47.47% | 49.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.32% | -28.73% | -4.50% | 20.96% | 27.69% |
| Operating Income | 20.75% | 28.98% | 6.47% | -18.50% | -27.69% |
| Income Before Tax | -395.93% | -123.07% | 15.11% | 53.81% | 113.27% |
| Income Tax Expenses | -55,621.43% | -55,521.43% | -55,521.43% | 0.00% | 0.00% |
| Earnings from Continuing Operations | -388.61% | -119.74% | 17.17% | 53.81% | 113.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -388.61% | -119.74% | 17.17% | 53.81% | 113.27% |
| EBIT | 20.75% | 28.98% | 6.47% | -18.50% | -27.69% |
| EBITDA | 20.79% | 29.02% | 6.49% | -18.50% | -27.66% |
| EPS Basic | -192.46% | 47.25% | 76.01% | 86.30% | 111.92% |
| Normalized Basic EPS | -196.94% | 47.97% | 77.12% | 88.29% | 111.28% |
| EPS Diluted | 11.12% | 65.76% | 83.00% | 89.82% | 87.55% |
| Normalized Diluted EPS | -209.93% | 49.45% | 77.62% | 88.50% | 109.95% |
| Average Basic Shares Outstanding | 121.62% | 105.05% | 87.58% | 82.31% | 92.10% |
| Average Diluted Shares Outstanding | 116.84% | 99.79% | 82.07% | 76.07% | 96.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |